Phillip Fitzsimmons
@Hennion & Walsh Asset Management, Inc.
Latest period2024 - Q4ReportedManaged Assets$2.209BTotal holdings851
Assets growth rate3.15%Assets growth rate (2-Q avg)6.59%Continuous growth in asset value5 quarters
Portfolio positions
This chart displays the top 10 holdings in Hennion & Walsh Asset Management, Inc.'s 2024 - Q4 portfolio, based on their 13F SEC filing, out of a total of 851 positions.
Assets under management
The assets under management (AUM) of Hennion & Walsh Asset Management, Inc. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 5 quarters. As of the latest 13F SEC filing for 2024 - Q4, they manage 2.209B in assets, with a quarterly growth rate of 3.15% and a 2-quarter average growth rate of 6.59%. The portfolio is managed by Phillip Fitzsimmons, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
CVSCvs Health Corp
| 0% | $535,423 8,515 shares@ $62.88 avg price | Exited |
TVTXTravere Therapeutics Inc
| 0% | $512,090 36,604 shares@ $14.0 avg price | Exited |
APTVAptiv Plc
| 0% | $500,470 6,950 shares@ $72.02 avg price | Exited |
RFRegions Financial Corp New
| 0% | $491,936 21,086 shares@ $23.33 avg price | Exited |
IDCCInterdigital Inc
| 0% | $487,349 3,441 shares@ $141.64 avg price | Exited |
SCHDSchwab Strategic Tr
| 0% | $486,132 5,751 shares@ $84.53 avg price | Exited |
BKEBuckle Inc
| 0% | $463,708 10,546 shares@ $43.98 avg price | Exited |
ARWRArrowhead Pharmaceuticals In
| 0% | $436,135 22,516 shares@ $19.38 avg price | Exited |
ARQTArcutis Biotherapeutics Inc
| 0% | $408,902 43,968 shares@ $9.3 avg price | Exited |
JPINuveen Pfd Secs & Inc Oppty
| 0% | $361,269 17,352 shares@ $20.83 avg price | Exited |